Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity

Pediatr Blood Cancer. 2013 Feb;60(2):338-9. doi: 10.1002/pbc.24325. Epub 2012 Sep 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Child
  • Child, Preschool
  • Daunorubicin / therapeutic use
  • Doxorubicin / adverse effects*
  • Drug Substitution / adverse effects*
  • Female
  • Humans
  • Induction Chemotherapy / adverse effects
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Daunorubicin